Search

Your search keyword '"Leppa, Sirpa"' showing total 15 results
Start Over Author "Leppa, Sirpa" Publication Year Range Last 3 years
15 results on '"Leppa, Sirpa"'

1. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma

Author

Meriranta, Leo, primary, Sorri, Selma, additional, Huse, Kanutte, additional, Liu, Xiaonan, additional, Spasevska, Ivana, additional, Zafar, Sadia, additional, Chowdhury, Iftekhar, additional, Dufva, Olli, additional, Sahlberg, Eerika, additional, Tandaric, Luka, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Hyytiainen, Marko, additional, Varjosalo, Markku, additional, Myklebust, June H., additional, and Leppa, Sirpa, additional

Published
2024
Full Text
View/download PDF

2. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial

Author

Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Jorgensen, Rasmus Rask Kragh, El-Galaly, Tarec Christoffer, Riise, Jon, Leppa, Sirpa, Christensen, Jacob Haaber, Sonnevi, Kristina, Pedersen, Lone Bredo, Wader, Karin Fahl, Glimelius, Ingrid, Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Jorgensen, Rasmus Rask Kragh, El-Galaly, Tarec Christoffer, Riise, Jon, Leppa, Sirpa, Christensen, Jacob Haaber, Sonnevi, Kristina, Pedersen, Lone Bredo, Wader, Karin Fahl, and Glimelius, Ingrid

Abstract

Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6 months. After dose escalation, the recommended phase 2 dose was lenalidomide 20 mg daily, days 1 to 21; venetoclax 600 mg daily after ramp-up; and rituximab 375 mg/m(2) weekly for 4 weeks, then every 8 weeks. MRD monitoring by RQ-PCR was performed every 3 months. When MRD-negativity in the blood was reached, treatment was continued for another 3 months; if MRD-negativity was then confirmed, treatment was stopped. In total, 59 patients were enrolled, with a median age of 73 years. At 6 months, the ORR was 63% (29 complete remission [CR], 8 partial remission [PR]), and 40% (4 CR, 2 PR) for patients previously failing a Bruton tyrosine kinase (BTK) inhibitor. Median progression-free survival (PFS) was 21 months, with median overall survival of 31 months. TP53 mutation was associated with inferior PFS (P < .01). Overall, 28 patients (48%) discontinued treatment in molecular remission, and 25 remain MRD negative after a median of 17.4 months. Hematological toxicity was frequent, with 52 of 59 (88%) patients with G3-4 neutropenia and 21 of 59 (36%) patients with G3-4 thrombocytopenia. To conclude, MRD-driven venetoclax-R2 is feasible and tolerable and shows efficacy in R/R MCL, also after BTK inhibitor failure.

Published
2024
Full Text
View/download PDF

3. S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Author

Sureda, Anna, primary, Falchi, Lorenzo, additional, Leppa, Sirpa, additional, Vermaat, Joost, additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Merryman, Reid W., additional, Christensen, Jacob Haaber, additional, Wahlin, Bjorn, additional, Linton, Kim, additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Belada, David, additional

Published
2023
Full Text
View/download PDF

4. P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Author

Hutchings, Martin, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Dickinson, Michael, additional, Bachy, Emmanuel, additional, Cartron, Guillaume, additional, Khan, Cyrus, additional, Tani, Monica, additional, Martinez-Lopez, Joaquín, additional, Bartlett, Nancy L., additional, Salar, Antonio, additional, Brody, Joshua, additional, Leppa, Sirpa, additional, Baumlin, Pauline, additional, Lundberg, Linda, additional, Relf, James, additional, Xie, Yuying, additional, Bottos, Alessia, additional, Humphrey, Kathryn, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

5. Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

Author

Koff, Jean L., primary, Kositsky, Rachel, additional, Jaye, David L, additional, Churnetski, Michael C., additional, Baird, Katelin, additional, O'Leary, Colin B., additional, Flowers, Christopher R., additional, Leppa, Sirpa, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Li, Shaoying, additional, Xu, Jie, additional, Pedersen, Mette Ø, additional, Gang, Anne Ortved, additional, Naresh, Kikkeri N, additional, Leeman-Neill, Rebecca J, additional, Au Yeung, Kwok Him Rex, additional, Qureishi, Hina Naushad, additional, Iqbal, Javeed, additional, Chapman-Fredricks, Jennifer R, additional, McCall, Chad M., additional, Crump, Michael, additional, Chadburn, Amy, additional, Mulvey, Erin C., additional, Lossos, Izidore S., additional, Ondrejka, Sandra L., additional, Hsi, Eric D., additional, Louissaint, Abner, additional, Martin, Haley, additional, Tse, Eric, additional, Love, Cassandra, additional, Dave, Tushar, additional, Parker, Clay, additional, Ong, Choon Kiat, additional, Evans, Andrew G, additional, Behdad, Amir, additional, Yang, Lixin, additional, Reddy, Nishitha, additional, Arildsen, Mary Ann, additional, Juskevicius, Ridas, additional, Yan, Jiong, additional, Czader, Magdalena, additional, Evens, Andrew M., additional, Soliman, Dina Sameh, additional, Fedoriw, Yuri, additional, Dave, Sandeep S., additional, and Cohen, Jonathon B., additional

Published
2022
Full Text
View/download PDF

7. Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Author

Leppa, Sirpa, primary, Jørgensen, Judit M., additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Beiske, Klaus, additional, Pedersen, Mette, additional, Drott, Kristina, additional, Pasanen, Annika, additional, Karihtala, Kristiina, additional, Mannisto, Susanna, additional, Meriranta, Leo, additional, Wold, Bente, additional, Brodtkorb, Marianne, additional, Fagerli, Unn Merete, additional, Larsen, Thomas S., additional, Munksgaard, Lars, additional, Sunela, Kaisa, additional, Fluge, Øystein, additional, Jyrkkio, Sirkku, additional, Brown, Peter de Nully, additional, and Holte, Harald, additional

Published
2022
Full Text
View/download PDF

9. Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Author

Arffman, Maare, primary, Meriranta, Leo, additional, Holte, Harald, additional, Jørgensen, Judit, additional, Brown, Peter De Nully, additional, Jyrkkio, Sirkku, additional, Jerkeman, Mats, additional, Fluge, Øystein, additional, Björkholm, Magnus, additional, Autio, Matias, additional, Leivonen, Suvi-Katri, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

10. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Author

Dreyling, Martin, primary, Doorduijn, Jeanette K., additional, Gine, Eva, additional, Jerkeman, Mats, additional, Walewski, Jan, additional, Hutchings, Martin, additional, Mey, Ulrich, additional, Riise, Jon, additional, Trneny, Marek, additional, Vergote, Vibeke K.J., additional, Celli, Melania, additional, Shpilberg, Ofer, additional, Gomes da Silva, Maria, additional, Leppa, Sirpa, additional, Jiang, Linmiao, additional, Pott, Christiane, additional, Klapper, Wolfram, additional, Gözel, Döndü, additional, Schmidt, Christian, additional, Unterhalt, Michael, additional, Ladetto, Marco, additional, and Hoster, Eva, additional

Published
2022
Full Text
View/download PDF

11. Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Author

Kalashnikov, Ilja, primary, Karjalainen-Lindsberg, Marja-Liisa, additional, Kovanen, Panu, additional, Dunkel, Johannes, additional, Pasanen, Annika, additional, Kositsky, Rachel, additional, Ondrejka, Sarah L., additional, Hsi, Eric D., additional, Evans, Andrew G, additional, Pedersen, Mette Ø, additional, Norgaard, Peter H., additional, Gang, Anne Ortved, additional, Czader, Magdalena, additional, Zhou, Jiehao, additional, Xu, Mina L, additional, Paulson, Nathan, additional, Juskevicius, Ridas, additional, Natkunam, Yasodha, additional, Louissaint, Abner, additional, Martin, Haley, additional, Thacker, Elizabeth, additional, Love, Cassandra, additional, Tian, Shari, additional, Ong, Choon Kiat, additional, Cheng, Chee Leong, additional, McCall, Chad M., additional, Koff, Jean L., additional, Younes, Sheren F., additional, Arildsen, Mary Ann, additional, Chapman-Fredricks, Jennifer R, additional, Amador, Catalina, additional, Fedoriw, Yuri, additional, Casulo, Carla, additional, Chadburn, Amy, additional, Sojitra, Payal, additional, Behdad, Amir, additional, Tse, Eric, additional, Naresh, Kikkeri N, additional, Yin, C. Cameron, additional, Goswami, Rashmi S., additional, Dave, Sandeep, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

13. Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma

Author

Leivonen, Suvi-Katri, primary, Friman, Terhi, additional, Vaittinen, Samuli, additional, Wind Jensen, Andreas, additional, d'Amore, Francesco Annibale, additional, Hamilton-Dutoit, Stephen Jacques, additional, Holte, Harald, additional, Beiske, Klaus, additional, Kovanen, Panu, additional, Räty, Riikka, additional, and Leppa, Sirpa, additional

Published
2022
Full Text
View/download PDF

14. Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim, Jurczak, Wojciech, Lugtenburg, Pieternella, Gyan, Emmanuel, Sureda Balari, Anna Maria, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Vitolo, Umberto, Cochrane, Tara, Leppa, Sirpa, Chamuleau, Martine E.D., Conlon, Rebekah, Favaro, Elena, Gernhardt, Diana, Altintas, Isil, Liu, Yan, and Thieblemont, Catherine

Published
2023
Full Text
View/download PDF

15. Mutations of ATMConfer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

Author

Koff, Jean L., Kositsky, Rachel, Jaye, David L, Churnetski, Michael C., Baird, Katelin, O'Leary, Colin B., Flowers, Christopher R., Leppa, Sirpa, Karjalainen-Lindsberg, Marja-Liisa, Li, Shaoying, Xu, Jie, Pedersen, Mette Ø, Gang, Anne Ortved, Naresh, Kikkeri N, Leeman-Neill, Rebecca J, Au Yeung, Kwok Him Rex, Qureishi, Hina Naushad, Iqbal, Javeed, Chapman-Fredricks, Jennifer R, McCall, Chad M., Crump, Michael, Chadburn, Amy, Mulvey, Erin C., Lossos, Izidore S., Ondrejka, Sandra L., Hsi, Eric D., Louissaint, Abner, Martin, Haley, Tse, Eric, Love, Cassandra, Dave, Tushar, Parker, Clay, Ong, Choon Kiat, Evans, Andrew G, Behdad, Amir, Yang, Lixin, Reddy, Nishitha, Arildsen, Mary Ann, Juskevicius, Ridas, Yan, Jiong, Czader, Magdalena, Evens, Andrew M., Soliman, Dina Sameh, Fedoriw, Yuri, Dave, Sandeep S., and Cohen, Jonathon B.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results